liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up
Lund University Hospital.
Lund University.
Lund University.
Linköping University, Department of Clinical and Experimental Medicine, Oncology . Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Centre of Surgery and Oncology, Department of Oncology UHL.
Show others and affiliations
2010 (English)In: BREAST CANCER RESEARCH AND TREATMENT, ISSN 0167-6806, Vol. 120, no 2, 491-498 p.Article in journal (Refereed) Published
Abstract [en]

Triple-negative breast cancer (TNB) has poor prognosis and moreover patients with TNB do not benefit from established targeted drugs with endocrine therapy or trastuzumab. The aim of the study was to analyze the prevalence of candidate biomarkers in tumors from patients with TNB. Tissue microarrays were prepared from primary tumors from premenopausal breast cancer patients (500/564) randomized to adjuvant tamoxifen or no adjuvant treatment. Immunohistochemical (IHC) staining included ER, PR, HER2, epidermal receptor growth factor (EGFR), vascular endothelial growth factor A (VEGF-A), and vascular endothelial growth factor receptor 2 (VEGFR2). EGFR and HER2 gene copy number was defined by fluorescence in situ hybridization (FISH). All patients were included in the descriptive analysis, but only untreated patients in the survival analysis. TNB was diagnosed in 96 patients and correlated significantly to low age, Nottingham histological grade (NHG) III, high Ki67-index, T2 tumors, node negativity, EGFR positivity, increased EGFR gene copy number and high VEGFR2 expression. TNB was an independent prognostic factor for decreased 5-year breast cancer specific survival (BCSS) (HR 2.0 (95% CI 1.1-3.6), P = 0.01), but not for 10-year BCSS. High VEGFR2 expression was significantly correlated to decreased BCSS in TNB patients. TNB was associated with decreased BCSS and clinicopathological characteristics of an aggressive tumor type. High VEGFR2 expression, EGFR expression, and EGFR gene copy number were significantly correlated to TNB, supporting their role as putative candidate biomarkers for selection of targeted therapy in TNB.

Place, publisher, year, edition, pages
2010. Vol. 120, no 2, 491-498 p.
Keyword [en]
Triple-negative breast cancer, Epidermal growth factor receptor, Gene copy number, Vascular endothelial growth factor receptor 2, Prognosis
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-54716DOI: 10.1007/s10549-010-0758-6ISI: 000275633300024OAI: diva2:308395
Available from: 2010-04-06 Created: 2010-04-06 Last updated: 2010-04-06

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Stål, Olle
By organisation
Oncology Faculty of Health SciencesDepartment of Oncology UHL
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 16 hits
ReferencesLink to record
Permanent link

Direct link